The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

But 25-year-old Madison Burgess has thrown caution to the wind by opting to micro-dose the drug. The Michigan native revealed ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

From lemon coffee to oatzempic, there's always a new weight loss hack people are buzzing about. The latest of these is ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

The FDA announced the end of the shortage of Novo Nordisk's drugs, Wegovy and Ozempic, which will impact sales of cheaper compounded versions. Compounded copies of Eli Lilly's drugs, Zepbound and ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.